Trial Profile
Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs BCG vaccine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 05 May 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 05 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jun 2009 Additional lead trial investigator identified as Andreas Schrodter as reported by ClinicalTrials.gov.